Lung Non-Squamous Non-Small Cell Carcinoma

Lung Non-Squamous Non-Small Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

408 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 93
Recruiting: 47
Ph III recruiting: 15
Growth YoY: —
Industry share: 39%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (56)

clinicaltrialsPublishedShowing 1–7 of 7 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07739186	A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)	not yet recruiting	Phase 2 / Phase 3	120	Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY	1	Aug 26, 2026	clinicaltrials
NCT07416058	PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC(PHOENIX)	not yet recruiting	Phase 2	61	Guangdong Association of Clinical Trials